🎉 M&A multiples are live!
Check it out!

Ligand Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ligand Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Ligand Pharmaceuticals Overview

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.


Founded

1987

HQ

United States of America
Employees

68

Website

ligand.com

Financials

LTM Revenue $174M

LTM EBITDA $68.8M

EV

$1.8B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ligand Pharmaceuticals Financials

Ligand Pharmaceuticals has a last 12-month revenue of $174M and a last 12-month EBITDA of $68.8M.

In the most recent fiscal year, Ligand Pharmaceuticals achieved revenue of $167M and an EBITDA of $40.8M.

Ligand Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ligand Pharmaceuticals valuation multiples based on analyst estimates

Ligand Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $131M $167M XXX XXX XXX
Gross Profit $143M $121M XXX XXX XXX
Gross Margin 109% 72% XXX XXX XXX
EBITDA $100.0M $40.8M XXX XXX XXX
EBITDA Margin 76% 24% XXX XXX XXX
Net Profit -$33.4M $52.2M XXX XXX XXX
Net Margin -25% 31% XXX XXX XXX
Net Debt $31.7M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ligand Pharmaceuticals Stock Performance

As of April 15, 2025, Ligand Pharmaceuticals's stock price is $107.

Ligand Pharmaceuticals has current market cap of $2.1B, and EV of $1.8B.

See Ligand Pharmaceuticals trading valuation data

Ligand Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.8B $2.1B XXX XXX XXX XXX $5.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ligand Pharmaceuticals Valuation Multiples

As of April 15, 2025, Ligand Pharmaceuticals has market cap of $2.1B and EV of $1.8B.

Ligand Pharmaceuticals's trades at 10.4x LTM EV/Revenue multiple, and 26.2x LTM EBITDA.

Analysts estimate Ligand Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ligand Pharmaceuticals and 10K+ public comps

Ligand Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.8B XXX XXX XXX
EV/Revenue 10.8x XXX XXX XXX
EV/EBITDA 44.2x XXX XXX XXX
P/E -509.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 23.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ligand Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ligand Pharmaceuticals Valuation Multiples

Ligand Pharmaceuticals's NTM/LTM revenue growth is 17%

Ligand Pharmaceuticals's revenue per employee for the last fiscal year averaged $2.5M, while opex per employee averaged $2.0M for the same period.

Over next 12 months, Ligand Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ligand Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ligand Pharmaceuticals and other 10K+ public comps

Ligand Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 27% XXX XXX XXX XXX
EBITDA Margin 24% XXX XXX XXX XXX
EBITDA Growth -59% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 41% XXX XXX XXX XXX
Revenue per Employee $2.5M XXX XXX XXX XXX
Opex per Employee $2.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 47% XXX XXX XXX XXX
R&D Expenses to Revenue 13% XXX XXX XXX XXX
Opex to Revenue 80% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ligand Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ligand Pharmaceuticals M&A and Investment Activity

Ligand Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Ligand Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ligand Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ligand Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ligand Pharmaceuticals

When was Ligand Pharmaceuticals founded? Ligand Pharmaceuticals was founded in 1987.
Where is Ligand Pharmaceuticals headquartered? Ligand Pharmaceuticals is headquartered in United States of America.
How many employees does Ligand Pharmaceuticals have? As of today, Ligand Pharmaceuticals has 68 employees.
Who is the CEO of Ligand Pharmaceuticals? Ligand Pharmaceuticals's CEO is Mr. Todd C. Davis.
Is Ligand Pharmaceuticals publicy listed? Yes, Ligand Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Ligand Pharmaceuticals? Ligand Pharmaceuticals trades under LGND ticker.
When did Ligand Pharmaceuticals go public? Ligand Pharmaceuticals went public in 1995.
Who are competitors of Ligand Pharmaceuticals? Similar companies to Ligand Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Ligand Pharmaceuticals? Ligand Pharmaceuticals's current market cap is $2.1B
What is the current revenue of Ligand Pharmaceuticals? Ligand Pharmaceuticals's last 12-month revenue is $174M.
What is the current EBITDA of Ligand Pharmaceuticals? Ligand Pharmaceuticals's last 12-month EBITDA is $68.8M.
What is the current EV/Revenue multiple of Ligand Pharmaceuticals? Current revenue multiple of Ligand Pharmaceuticals is 10.4x.
What is the current EV/EBITDA multiple of Ligand Pharmaceuticals? Current EBITDA multiple of Ligand Pharmaceuticals is 26.2x.
What is the current revenue growth of Ligand Pharmaceuticals? Ligand Pharmaceuticals revenue growth between 2023 and 2024 was 27%.
Is Ligand Pharmaceuticals profitable? Yes, Ligand Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.